1998

Keio University, M.D.

2002

Research Assistant, Keio University (Ophthalmology)

2008

Assistant Professor, Keio University (Ophthalmology)

2013

Specially Appointed Lecturer, Keio University (Ophthalmology)

2015

Founder & CEO, Cellusion

2009

Postdoctoral Fellow, Memorial Sloan Kettering Cancer Center

2011

Senior Researcher, Astellas Pharma

2019

CFO, Executive Officer, Cellusion

2020

CFO, Board Director, Cellusion

2021

CFO & COO, Board Director, Cellusion

2022

EVP & COO, Cellusion

1998

The Export-Import Bank of Japan
(currently Japan Bank for International Cooperation)

2006

Morgan Stanley Japan Securities
(currently Mitsubishi UFJ Morgan Stanley Securities)

2017

Executive Director, Mitsubishi UFJ Morgan Stanley Securities

2022

CFO, Cellusion

2023

CFO, Executive Officer, Cellusion

2024

CFO, Board Director, Cellusion

2000

Hitachi Software Engineering (currently Hitachi Solutions)

2006

Oncolys BioPharma

2008

SBI Intechstra

2011

Oji Paper (currently Oji Holdings)

2019

YAMASHIN-FILTER

2022

Director, IP & Legal Department, Cellusion

2024

Executive Officer, Director, IP & Legal Department, Cellusion

1992

Researcher, Kyowa Hakko Kogyo
(currently Kyowa Kirin)

2000

Manager, Kyowa Pharmaceutical

2017

Director, Kyowa Kirin

2021

CDO, Cellusion

2013

Rakuten Group

2016

Assistant Manager & China Country Manager, Rakuten Group

2017

Investment Director, Industrial Technology Investment Corporation
(-present)

2022

Outside Director, Cellusion

2000

Assistant Professor, Columbia University

2006

Manager, GlaxoSmithKline

2006

Banyu Pharmaceutical

2008

Director, Merck & Co.

2012

Deputy General Manager, Taisho Pharmaceutical

2015

Senior Director, Japan ES&I lead, Pfizer Inc

2019

APAC Lead and Senior Director, Pfizer Inc

2021

CEO, BioLite Japan (-present)

2021

CEO, Lucidaim (-present)

2021

Outside Director, Cellusion

2022

CEO, Newsight Tech Angels (-present)

2006

Summit Pharmaceuticals International Corporation (SPI)

2010

Head of Biology Group, SPI

2016

Executive Officer, Keio Innovation Initiative (-present)

2017

Outside Director, Cellusion

2010

Physician, The University of Tokyo Hospital and Hitachi General Hospital

2014

Medical Director, Japanese Organization for Medical Device Development

2018

Manager, Boston Scientific Corporation Japan

2019

Principal, The University of Tokyo Edge Capital Partners
(-present)

2021

Outside Corporate Auditor, Cellusion

2023

Outside Director, Cellusion

2010

Daiwa Securities Capital Markets Co. Ltd. (currently Daiwa Securities Co. Ltd.)

2018

Innovation Network Corporation of Japan (currently INCJ, Ltd.)

2020

Principal, JIC Venture Growth Investments Co., Ltd. (-present)

2023

Outside Director, Cellusion

1979

Special Reference Laboratories
(currently SRL)

2005

Executive Officer, General Manager, SRL

2007

Director, General Manager, SRL

2012

Corporate Auditor, Fujirebio

2017

Executive Director, General Manager, SRL

2018

Corporate Auditor, IDAC Theranostics

2022

Corporate Auditor, Cellusion

1996

Ministry of International Trade and Industry (currently The Ministry of Economy, Trade and Industry)

2004

The University of Tokyo Edge Capital Co., Ltd.

2015

Managing Director, Japan Venture Capital Association

2018

CEO and President, Managing Partner, The University of Tokyo Edge Capital Partners Co., Ltd. (-present)

2022

Vice Chairman, Japan Venture Capital Association

2023

Chairman, Japan Venture Capital Association (-present)

2023

Outside Corporate Auditor, Cellusion

1988

The Hokkaido Takushoku Bank, Ltd.

1998

Daiwa Securities Co. Ltd.

2018

Outside Full-Time Auditor, Japan Management Succession Support Co. Ltd. (-present)

2023

Outside Corporate Auditor, Cellusion

1994

The Legislative Bureau of the House of Representatives

1997

KOGA & PARTNERS

2000

Nishimura & Partners (currently Nishimura & Asahi)

2006

Ito & Mitomi (currently Morrison Foerster)

2011

Novartis Holding Japan K.K

2012

Head, Legal & Compliance Office, SANDOZ K.K.

2014

Head of Pharma Legal Department, Novartis Pharma K.K.

2016

Corporate Officer, General Counsel, Head of Legal & IP and Country Legal Head, Novartis Pharma K.K.

2022

Director, International Legal, Alnylam Japan K.K. (-present)

2022

Outside Director, PRISM BioLab Co.,Ltd. (-present)

2023

Outside Corporate Auditor, Cellusion

Professor, University of California, Los Angeles
Director, UCLA Stein Eye Institute
An authority on corneal transplantation; has won numerous awards

• University of California, Los Angeles
• UCLA Stein Eye Institute
• The Illinois Eye and Ear Infirmary
• The University of Rochester

Associate Professor, Harvard Medical School
Associate Director, Massachusetts Eye and Ear
Member, Cornea Center of Excellence
An expert in corneal diseases; has won numerous awards

• Harvard Medical School
• Massachusetts Eye and Ear
• Boston University
• University of Louisville

Professor Emeritus of Tokyo Dental College
A specialist on corneal transplantation, corneal regenerative medicine, and treatment for severe ocular surface disease.

• Tokyo Dental College
• Shimazaki Eye Clinic
• Keio University Hospital
• Saiseikai Kanagawa Hospital

Has been involved in numerous clinical development projects for leading global pharmaceutical companies and CROs. Currently serves as CEO of his own consulting firm, Pharma Initiative Support

• Parexel
• Eli Lilly

Has over 30 years experience in the financial industry, including as Executive Officer, SMBC Nikko Securities, Managing Director, Morgan Stanley MUFG Securities, and at The Bank of Tokyo-Mitsubishi. Currently serves as CEO of his own consulting firm, KOMABA Planning

• SMBC Nikko Securities
• Morgan Stanley MUFG Securities
• Morgan Stanley
• The Bank of Tokyo-Mitsubishi

Has extensive experience in corporate branding and promotion having worked at PR companies, including Signal and Parco Digital Marketing. Former COO of Vector group company, Signal

• PARCO
• VECTOR
• PERSOL CAREER
• Light